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This national programme of obstructive sleep apnoea
deals with the prevention and treatment of the disease.
The term‘‘sleep apnoea’’ is used to refer to an illness that
results in daytime symptoms because of abnormal cessa-
tions of respiration during sleep.There are other forms
of sleep disorders but they are referred in this pro-
gramme only in connectionwith di¡erential diagnosis.
According to Finnish population studies, the Health
2000 survey by the National Public Health Institute (Ar-
omaa et al., 2002) and the register of hospital treatment
periods (HILMO) of Finnish National Research and De-
velopment Centre for Welfare and Health (Stakes), ap-
proximately 150 000 Finnish patients su¡er from sleep
apnoea.Up to 3% of middle-agedmen and 2% of middle-
aged women have the illness in Finland. The number of
patients with sleep apnoea and other sleep disorders is
underestimated by diagnosis and is increasing. The stu-
dies on theprevalence of sleep apnoea in other countries
have ¢gures from 0.8% (Gleadhilletal.,1991) to10% (Bear-
parket al.,1995).
Obesity is themost importantrisk factor for sleep ap-
noea.The main target of prevention and treatment is to
achieve lower weight and weight control. Other treat-
mentmethods of sleep apnoea, particularly nasal contin-
uous positive air pressure (n-CPAP) treatment, are
individually initiated by specialist care.Themain respon-
sibility for helpingpatients in reducingweight andweight
controlwill be in public health care.
The national programme has the following goals: (1) a
decrease in the incidence of sleep apnoea; (2) full recov-
ery of as many sleep apnoea patients as possible; (3)
maintenance of good functional and working ability of
sleep apnoea patients; (4) a decrease in the number of
patients with severe sleep apnoea; (5) a decrease in the
number of sleep apnoea patients requiring hospitalisa-
tion; and (6) an improvement in the cost^ e¡ect ratio ofReceived 8 August 2002, accepted in revised form 8 Aaugusst 2002
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E-mail: anne.pietinalho@¢lha.¢sleep apnoea treatment. The most important measures
towards achieving these goals include: (1) stepping up
prevention of obesity and promoting weight reduction
andweightcontrol; (2) ensuring children’s nasalbreathing
and intensifying the removal of obstructive adenoid tis-
sue; (3) steeping up treatment of malocclusions and de-
viations in maxillomandibular growth in children; (4)
increasing key group’s knowledge of risk factors of sleep
apnoea and the treatment of the disease; (5) stepping up
earlydiagnostics and active treatment; (6) initiating early
individual rehabilitation as part of the treatment; and (7)
emphasising the importance of research.
The implementation of this national programme is
vital. Regional direction and training will mainly be
organized by hospital districts and/or provincial govern-
ments and local health-care centres. Special attention
mustbepaid on the evaluation of the success of sleep ap-
noea prevention and treatment. Both special follow-up
studies by Finnish Lung Health Association and popula-
tion studies by the National Public Health Institute as
well as HILMO by Stakes will be used in the evaluation
of the programme.
FOREWORD
Sleep apnoea is a disease a¡ecting approximately150 000
Finns. Untreated sleep apnoea not only leads to an in-
crease in mortality, the number of accidents, and the in-
cidence of cardiovascular diseases, but also reduces
working and functioning capacity, and undermines the
quality of life. The signi¢cance of the problem in terms
of national health and economy, the increasing patient
numbers, the knowledge of improved possibilities for
preventing and treating the disease, and the need for
large-scale collaboration create the foundation for a na-
tional prevention programme.
After reaching an agreementwith the FinnishMinistry
of Social A¡airs and Health, the Finnish Lung Health As-
sociation appointed a working group to prepare a pro-
gramme for the prevention and treatment of sleep
apnoea for a10-year period from 2002 to 2012. Professor
and Managing Director Lauri A. Laitinen from the
Hospital District of Helsinki and Uusimaa was elected
338 RESPIRATORYMEDICINEchairman of the working group. The other members
were Docent Antti Ahonen from Helsinki University
CentralHospital, JukkaAntila (MD)PhD fromTurkuUni-
versity Central Hospital, JaakkoHerrala (MD) PhD from
Tampere University Hospital, Docent Raimo Isoaho
from Turku University, Turkka Kirjavainen (MD) PhD,
Docent Paula Maasilta and Docent Pertti Mustajoki
from Helsinki University Central Hospital, Docent
Markku Partinen from Haaga Neurological Research
Centre (NEURO),ProfessorOlli Polo fromTurkuUniver-
sity, Docent Tapani Salmi from Helsinki University Cen-
tral Hospital, and Kimmo VNhNtalo (Specialist in
Dentistry) fromTurku University Central Hospital.
At ¢rst, PNivi HNmNlNinen (MD) PhD from the provin-
cial government ofWestern Finland served as the secre-
tary of the working group. She was succeeded by Ulla
Anttalainen (MD) fromTurku University Central Hospi-
tal and Anne Pietinalho (MD) PhD from the Finnish Lung
HealthAssociation.ProfessorKajKoskela, the Secretary
General of the Finnish LungHealthAssociation, also par-
ticipated in the work of the working group.The experts
consulted during the process were Kimmo LehtimNki
DSc (Dental Sience) and Docent Heli Vinkka-Puhakka
from Tampere University Central Hospital and Juha
Markkula (Specialist in Psychiatry) from the sleep work-
ing group of Turku University Central Hospital.
Statements about the programme have beenmade by
—land Central Hospital, South Karelia Central Hospital,
the provincial government of Southern Finland, Helsinki
University Central Hospital, the Pulmonary Association
HELI, JorviHospital, theNational PublicHealth Institute,
Kanta-HNme Pulmonary Society, Kuopio University
Hospital, Lohja Hospital, the provincial government of
Western Finland,Mikkeli Central Hospital,Oulu Univer-
sity Hospital, North Karelia Hospital District, PNijNt-
HNme Central Hospital, Satakunta Central Hospital, Sa-
vonlinna Central Hospital, SeinNjoki Central Hospital,
Stakes, the Finnish Medical Society Duodecim, the Fin-
nish Dental Association, the Association of Finnish Pul-
monary Physicians, the Finnish Society of Clinical
Physiology, the Finnish Paediatric Association, the Fin-
nish Medical Association, the Finnish Neurological So-
ciety, the Association of Finnish Otolaryngologists, the
Finnish Sleep Research Society,TampereUniversity Hos-TABLE 1. De¢nitions relating to sleep apnoea
Term De¢nition
Apnoea Acomplete interruption i
Obstructive apnoea Arespiratory interruptio
Central apnoea Arespiratory interruptio
Mixed apnoea Arespiratory interruptio
Hypopnoea Decreasedrespiratory aipital, the Union of Health and Social Care Professionals,
Turku Pulmonary Association, Turku University Central
Hospital, Turku University Institute of Clinical Medicine
and the Finnish Sleep Federation.
The national programme is a recommendation to be
applied to the prevention and treatment of sleep apnoea
throughout the ¢eld of health care. The programme
should be revised when necessary asmedical knowledge
increases and the equipment andmedical treatments de-
velop. The patient and the health-care professional and
unit treating him are responsible for the actual treat-
ment. The programme is based on numerous study re-
sults, reports and practical experience. Detailed
references to published material are not given in the
text, but examples of key literature have been gathered
in an Appendix.
The Ministry of Social A¡airs and Health hopes that
the programme will become a practical tool in the pre-
vention of sleep apnoea.
Markku Lehto
Permanent Secretary
SLEEPAPNOEAASANILLNESS
De¢nitions
Occasional short-term interruptions in breathing occur
during normal sleep. If the episodes are long-term or fre-
quent and result in symptoms during waking hours, the
condition can be de¢ned as sleep apnoea. In literature,
the terms sleep apnoea syndrome or sleep apnoea illness
are also used. In this programme, the term sleep apnoea
is used to refer to an illness with abnormal respiratory
interruptions during sleep.
Various forms of sleep apnoea and the associated
terms are explained inTable 1.The events of obstructive
apnoea are described in Appendix 1. This programme
deals with the prophylaxis and treatment of obstructive
sleep apnoea. Reference to other sleep disorders is only
made in connectionwith di¡erential diagnosis.
The de¢nitions of sleep apnoea combine the symp-
toms of the patient and the ¢ndings from various test
methods. Table 2 shows the diagnostic criteria of sleep
apnoea in adults suitable for clinical work. Specialnrespiratory air £owlastingZ10 s
nwhereno air £owis detected despite respiratorye¡ort
nwithoutrespiratorye¡ort
nthat is a combination of obstructive and central sleep apnoea
r £ow
TABLE 2. Diagnostic criteria of sleep apnoea (mild sleep apnoea A+B+C, moderate-to-severe+D)
(A) Symptomsinclude abnormal daytime fatigue or restless sleep.The patientdoesnot alwaysrecognise the symptoms.
(B) Recordedrecurrentrespiratory interruptions during sleep.
(C) Othercharacteristic features:
1.Snoring, especially intermittent
2. Morningheadaches
3.Dryness ofmouth onwaking
4.In children, paradoxalbreathingduring sleep
(D) More than ¢ve apnoea episodes orone ormore ofthe following ¢ndings recorded in sleep registration:
1. Recurrent arousals after apnoea episodes
2. Cyclicalvariation inpulse rate
3. Decrease in arterial oxygen saturation after apnoea episodes
4. Deviating sleep latency in MSLT test
(E) Maybe connected to other illnesses, e.g. large tonsils and adenoids
(F) Other sleep disordersmaybe included, e.g. restless legs ornarcolepsy
Source: International Classi¢cation of Sleep Disorders,Diagnostic and Coding Manual,American Academyof Sleep Medicine
2001, revised.
TABLE 3. Degrees of severityin sleep apnoea
 Mild sleep apnoea a: AHI 5^15/h, mild symptoms
 Moderate sleep apnoea: AHI16^30/h, moderate symptoms
 Severe sleep apnoea: AHI4 30/h, severe symptoms
aIn children agedunder12months, theresults are deviatingif AHIZ1/h.In adults agedover 70 years, theresults are deviating
if AHI415/h.
Possible sleep apnoea
Snoring
Respiratory interruptions
(AHI>5)
Daytime fatiguePartial
upper airways
obstruction
of
Sleep anpnoea
FIG. 1. Relationship of respiratory interruptions, daytime fati-
gue and snoring to sleep apnoea.
SLEEPAPNOEA 339features of sleep apnoea in children are discussed
in the chapter ‘‘Special features of sleep apnoea in chil-
dren’’.
Degrees of severity
The degree of severity is de¢nedon thebasis of the num-
ber of respiratory disruptions [apnoea-hypopnoea index
AHI] and the severity of daytime symptoms. The AHI
shows how many episodes of apnoea and hypopnoea
have been detected during 1h of sleep. In practice, the
evaluation of the severity of sleep apnoea (Table 3) is
complicated by the fact that the number of respiratory
disruptions and the decrease in oxygen saturation mea-
suredby pulse oxymeter are not always directly propor-
tional to the patient’s symptoms.
Symptoms
The primary symptoms of sleep apnoea are respi-
ratory interruptions. Primary symptoms also include
abnormal daytime fatigue, whichmay bemanifested as a
tendency to doze o¡, a lack of concentration, or an
impairment of memory function. Snoring may be the¢rst sign of incipient obstruction of the airways.
Snoring associated with sleep apnoea is generally
habitual snoring, i.e. regular snoring occurring
almost every night. The relationship of the symptoms
to sleep apnoea is presented in Fig. 1 and the symp-
toms of sleep apnoea inTable 4.The evaluation of the se-
verity of the symptoms is explained in Appendix 2.The
special features of sleep apnoea in children are discussed
in the chapter ‘‘Special features of sleep apnoea in chil-
dren’’.
TABLE 4. Symptoms of sleep apnoea
Symptomswhile awake
 Daytime fatigue
 Morningheadaches
 Tendency to doze o¡
 Impairedmemory function
 Impaired concentration
 Mood changes, shorttemper, irritability
 Impotence, impaired libido
 Heartburn
Symptoms while asleep
 Loud snoring
 Respiratory interruptions reported by the sleeping
partner
 Restless sleep
 Night-time perspiration
 Increasedneed to urinate during the night
 Heartburn
Severe 15,000 High costs
Moderate 50,000 Moderate costs
Mild 85,000
Low costs
FIG 2. An estimate of the number of patients with sleep ap-
noea and the related costs based onthe incidence ¢gures in Fin-
land.
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FIG. 3. Number of patients diagnosed with sleep apnoea or
snoringadmitted for treatmentper annum (Stakes,HILMO).
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Sleep apnoea is a common illness occurring inup to 3% of
middle-aged men and 2% of middle-aged women in Fin-
land. It is feared that the incidence of the illness will con-
tinue to rise with the increasing obesity of the
population. A typical patient with sleep apnoea is a man
over 35 years of age or a postmenopausal woman. At
least 0.3% of all adult men below retirement age su¡er
from moderate-to-severe sleep apnoea. The illness also
occurs in women. The incidence of sleep apnoea peaks
amongmen aged 50^59 years (Appendix 3).
Respiratory disruptions during sleep are common in
the elderly even though they do not snore as often as
the middle aged. Of people aged over 65 years, one in
four has an apnoea index of more than10. However, the
numberof thosewith symptomatic sleep apnoea is lower
among the elderly than among middle-aged men, esti-
mated at 0.5^1%.
In the extensive Health 2000 survey, carried out on
10 000 subjects aged over18 years by theNational Public
Health Institute, approx. 7% of the Finns (approx.13% of
men and approx. 3% of women) reported having experi-
enced weekly sleep disruptions, and approx.1% (approx.
2% of men and under 0.5% of women) reported having
been diagnosedwith sleep apnoea.
The incidence of sleep apnoea in 5-year-old children in
Finland is estimated to be approx. 2%.The evaluation of
the incidence of sleep apnoea in children is complicated
by the fact that, in children, the illness is partly related
to the amount of adenoid tissue in the throat, and the
incidence of the illness may £uctuate at di¡erent ages.
Studies conducted outside Finland indicate that, among
children aged 4^6 years, 7^10% snore, and among chil-
dren aged 0.5^6 years, 2^3% su¡er from sleep apnoea.No di¡erence in the incidence of sleep apnoea with re-
gard to sex has been found among children, even though
boys snore slightlymore than girls.
Figure 2 shows an estimate of the sleep apnoea status
in Finland. According to the HILMO register of Stakes,
6645 patients were diagnosed with sleep apnoea; the
number of treatment periods was 8993; and the number
of hospital days was 12 803 in 2000. Treatment duration
averaged 1.4 days. In 2000, 2908 patients were hospita-
lised for snoring, and the number of treatment days was
3582 (Figure 3). The halt in the rise in patient numbers
and treatment days was not caused by a reduction in
the incidence or alleviation of the illness, but rather by
the fact that sleep registration follow-ups requiring
many hospital days have been reduced by increasing out-
patient activity.
The number of continuous positive airway pressure
(CPAP) devices used for the treatment of sleep apnoea
has been rising steadily in the 1990s. The number con-
tinues to rise. In 2000, there were approx. 150 users of
CPAP devices per 100 000 inhabitants in Finland. These
¢gures re£ect the number of diagnosed cases of moder-
ate-to-severe sleep apnoea. Figure 4 shows the regional
di¡erences in 2000 for the hospital districts (68^598/
100 000).
Apart from sleep apnoea, partial upper airways ob-
struction also involving increased respiratory resistance
6005004003002001000
Hospitals district of Helsinki and Uusimaa
Varsinais-Suomi
Satakunta
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East Savolax
North Karelia
North Savolax
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North Ostrobothnia
Kainuu
West Ostrobothnia
Lapland
Åland
FIG. 4. Number of CPAP-treated patients per100 000 inhabi-
tants perhospital district in 2000.
TABLE 5. Anatomical factors predisposing to sleep ap-
noea
1.Nose
 Oedema ofthe nasalmucosa
 Deviatednasal septum
 Nasalpolyps
 Large adenoids
2.Pharynx
 Anatomicallynarrowpharynx
 Increased adipose tissue ofthe upper respiratory tract
 Large tongue
 Large tonsils
 Enlarged soft palate
3.Jaw and face
 Micrognathia
 Jawlocated farther backwithrespectto the skull than
normal
 Narrowupper jaw
 Long face, longlower face
4.Body
 Central obesity, thickness of neck
SLEEPAPNOEA 341but no clear respiratory interruptions should be consid-
ered. Its precise incidence is still not known.
CAUSESANDRISKFACTORS
The development of upper airways obstruction causing
sleep apnoea is in£uencedby thephysiologyof sleep (Ap-
pendix1), and factors relating to anatomy andphysiology
(Tables 5 and 6).
CONSEQUENTEFFECTS
The qualityof life, the alertness, and the functional ability
of a patient su¡ering from sleep apnoea are impaired by
fatigue, concentration di⁄culties, mood changes and im-
paired libido. Cardiovascular symptoms in sleep apnoea
patientsrelate tohypoxia andincreasedbloodCO2 levels
during sleep, an increase in nocturnal respiratory e¡ort,
and an increase in sympathetic nervous activity (Table 7).
Sleep apnoea causes vasoconstriction and elevates both
systemic and pulmonary blood pressure.
SPECIALFEATURESOF SLEEP
APNOEAINCHILDREN
Themost important risk factors of sleep apnoea in chil-
dren are enlarged adenoids and tonsils. Moreover, sleep
apnoea is more common in children su¡ering from var-
ious syndromes or mental retardation than in children
in general. However, sleep apnoea is rare during infancy,
except in children with an apparent life-threatening
event (ALTE), up to 50% of whom su¡er from sleep ap-
noea. Mental retardation and the various syndromes in
children are associated with an increased disposition to
sleep apnoea. Removal of hyperplastic adenoid mass
may cure sleep apnoea in a child. If surgical interventionsare unsuccessful,CPAP treatment is an option to be con-
sidered.Obesity and thickness of neck in a child increase
the occurrence of sleep apnoea.
Sleep apnoea in childrenmay also result frommandib-
ular deviation andmalocclusion in childhood. About 20^
25% of children and adolescents have malocclusions
where the anterior growth of themandible is not paral-
lel with the growth of the other facial parts.Nasal con-
gestion, large adenoid tissue mass and oral breathing
have an unfavourable e¡ect on facial bone growth. Chil-
dren su¡ering from these problems develop a facial
structure where the growth of the mandible is directed
down rather than frontally. The face does not grow in
depth, and the airways do not gain enough space. Ade-
noid tissue surgery and orthodontics are used to guide
maxillomandibular growth and occlusion development
to the right direction.
Daytime fatigue or obesity are not typical symptoms
in paediatric sleep apnoea, except in a very severe condi-
tion. In children, sleep apnoea causes restless sleep, snor-
ing, sweating, recurrent upper respiratory tract
infections, hyperactivity, impaired concentration, learn-
ing di⁄culties, and oral breathing. In severe sleep ap-
noea, serious cardiovascular complications, for example,
have been reported.
GOALSANDMEANSOF THE
PROGRAMME
The goals for the prevention, treatment and rehabilita-
tion of sleep apnoea for 2002^2012 arepresented in Table
TABLE 6. Physiological factors impairing sleep apnoea
1.Nose andpharynx
 Temporaryoedema ofthe nasalmucosa
 Decreasedmuscle tone inthe pharyngealregion
 Snoring
 Infections ofthe upper respiratory tract
2.Respiration-related factors
 Diminishedrespiratoryresponse to a decrease in blood oxygen saturation
 Diminishedrespiratoryresponse to an increase in blood CO2 levels
 Otherdisturbances in respiratoryregulation
 Diminishedrespiratoryoutput
 Poormobilityof the bony thorax
 Impaired function of respiratorymuscles
3.Factors decreasingmuscle tension and depressing CNS function
 Alcohol
 CNS depressants
 Sleep deprivation
TABLE 7. Long-termconsequente¡ects of sleep apnoea
 Impaired functional andworkingability, impaired quality
of life
 Accidents intra⁄c and attheworkplace
 Aggravation of cardiovasculardiseases
 Increasedriskof cerebral ischaemic attacks
 Aggravation ofmentalproblems
 Increasedmortality
TABLE 8. The goals for the prevention, treatment and
rehabilitation of sleep apnoea
1.Decrease in the incidence of sleep apnoea
2.Full recoveryof asmany sleep apnoea patients as
possible
3.Maintenance of good functional andworkingabilityof
sleep apnoea patients
4.Decrease inthe numberof patientswith severe sleep
apnoea
5.Decrease in thenumberof sleep apnoea patients requir-
inghospitalisation
6.Improvement in the cost^e¡ect ratio of sleep
apnoea treatment
342 RESPIRATORYMEDICINE8 and discussed in more detail later. Table 9 shows the
means of achieving these goals.
PREVENTIONOFSLEEPAPNOEA
ANDITSCONSEQUENCES
Possibilities of prevention
The risk of developing sleep apnoea may be reduced by
in£uencing the behaviour of the individual concerned,
by facilitating good treatment of the predisposing ill-
nesses (primary prevention) and also by improving the
early detection of sleep apnoea and the motivation of
the patientwith regard to his own treatment (secondary
prevention).Good treatment of sleep apnoea, rehabilita-
tion and therapy of concomitant illnesses may help re-
duce the individual handicap caused by the illness
(tertiary prevention).
Thebasis for theprevention comprises both individual
(risk groups) and national interventions (Tables10^12).
The improvements in the standard of living have
resulted in changes in the society and in lifestyles that
predispose to obesity.Nationwide prevention of obesityrequires interventions at di¡erent levels of society to
further reduce the dietary intake of fat and to increase
the physical activity of the population.
Thismeans limiting the energy content of food, devel-
opment of school andworkplace canteen food, nutrition
and exercise guidance, development of light tra⁄c, ex-
tensive education and cooperation as well as research.
Persistent upper respiratory tract infections and
other factors complicating nasal breathing, such as large
adenoids and tonsils, allergyor irritationdue topoor am-
bient air, predispose to the development of sleep apnoea
as early as in childhood. In£uenza, haemophilus and
pneumococcal vaccines are used to counteract infec-
tions. At national level, reminding people about
the importance of hand washing can reduce the conta-
giousness of respiratory infections.Good hygiene in day-
care centres has also been found to reduce infections in
children.
TABLE 9. Means of achieving the goals of the sleep apnoea programme
1.Steppingup prevention of obesity andpromotingweightreduction andweightcontrol
2.Ensuringchildren’s nasal breathingand intensifying the removal of obstructive adenoid tissue
3.Steppinguptreatmentofmalocclusions and deviations inmaxillomandibular growth in children
4.Increasingkeygroupknowledge ofthe risk factors of sleep apnoea and the treatmentofthe disease
5.Steppingup earlydiagnostics and active treatment
6.Initiating individualrehabilitation earlyon as partofthe treatment
7.Emphasising the importance of research
TABLE 10. Preventing the development of sleep
apnoea (primaryprevention)
 Maintainingnormalweight
 Ensuringnasal andrespiratory tract function
 Removingenlarged adenoid tissue
 Initiatingearly treatmentofmalocclusions
 Abstaining from smokingandreducing the use of
alcohol
 Reducing the use of CNS depressants
TABLE 11. Earlydetectionandtreatmentof sleepapnoea
(secondaryprevention)
 Weightreduction andweightcontrol
 Elimination of factors causingnasal congestion
 Regularday/night rhythm
 Consideringriskgroups inprimaryhealth care
 Earlydiagnosis of sleep apnoea
 Goodinitial treatment, motivating the patientwith
regard to his owntreatment
TABLE 12. Preventing the aggravation of sleep apnoea
(tertiaryprevention)
 Weightreduction andweightcontrol
 Good treatmentof concomitant illnesses
 Rehabilitation
SLEEPAPNOEA 343Oral breathing guides maxillomandibular growth and
occlusion development in an unfavourable direction. As
a result, the anatomy of the upper respiratory tract de-
velops to increase the risk of sleep apnoea. Rheumatoid
arthritis, particularly juvenile RA or other rare illnesses
such as acromegaly andhypothyroidism in£uence the de-
velopment of jaw size and position. Early detection and
treatment of these illnesses is a part of the prevention
of sleep apnoea.Smokers havebeen found to havemorerespiratory in-
terruptions than non-smokers. The di¡erence is elimi-
nated with the cessation of smoking.Giving up smoking
reduces the tendency to snore as the incidence of re-
spiratory tract infections andmucosal membrane oede-
ma of the airways decreases. The elimination of carbon
monoxide from the blood results in more e¡ective noc-
turnal oxygenation. The cessation of smoking often re-
sults inweight gain and, therefore, concomitant support
with weight control is needed.The consensus treatment
recommendation on abstinence from smoking to be is-
sued by the Finnish Medical Society Duodecim in 2002
will provide tools for guidance and treatment.
Alcohol decreases muscle tone in the nasopharynx
and impairs the function of the CNSregulatorymechan-
isms. Excessive use of alcohol and heavy drinking are the
commonest promoters of the risk factors of sleep ap-
noea. Alcohol also causes weight gain, increases central
obesity and visceral fat. A person with risk factors of
sleep apnoea should be instructed to avoid excessive use
of alcohol.
CNS depressants impair sleep apnoea.Decreased use
of these agents would reduce the risk of sleep apnoea in
the population. Misuse of CNS depressants should be
tackled. The history of snoring should be recorded and
risk patients considered when prescribing the medica-
tion.
Prevention of sequelae
Once sleep apnoea has been diagnosed, the treatment
should be directed at the factors causing sleep apnoea
in each individual case. Successful treatment of sleep ap-
noea removes daytime fatigue and improves the quality
of life.
Eighteen per cent of the fatal road tra⁄c accidents ex-
aminedby theroad tra⁄c investigation teams are caused
by fatigue or falling asleep at the wheel. It is estimated
that people with untreated sleep apnoea are at a 6^7-
fold risk of having an accident compared to the rest of
the population. Controlled asymptomatic sleep apnoea
does not a¡ect driving. The risk in tra⁄c caused by se-
344 RESPIRATORYMEDICINEvere sleep apnoea is considered so high that, in cases
when the treatment is not e¡ective or the patient is re-
luctant to undergo treatment, the driving licence autho-
rities should be noti¢ed. According to current Finnish
legislation, a written consent from the patient is always
needed for this. When issuing medical certi¢cates for
driving licences, doctors should be able to refer all pa-
tientswith symptoms or anatomy suggestive of sleep ap-
noea to further evaluations. The application of the
sleepiness questionnaire in Appendix 2 couldbe apracti-
cal tool. If thepatient’s score is11or higher, specialist con-
sultation should be considered. The questionnaire can
also be applied to age group check-ups in occupational
health care.
A professional driver with untreated sleep apnoea
should be urgently referred to the initiation of the treat-
ment and, if necessary, sick leave should be considered
until the treatment can be initiated.
The treatmentof sleep apnoea reduces elevatedblood
pressure. If a patient with sleep apnoea su¡ers from hy-
pertension and the illness is not properly treated, treat-
ment should be organised. On the other hand, when
refractory hypertension is detected, the potential role
of sleep apnoea should be considered.
Outof sleep apnoea, asthma andCOPD, one is not the
cause of the other.However, these illnesses are so com-
mon that there are patients with concomitant sleep ap-
noea and asthma, or sleep apnoea and COPD, or all
three. Untreated asthma or COPD further impair the
oxygen uptake in a patient with sleep apnoea. Allergic
symptoms often related to asthma hamper nasal breath-
ing. Proper treatment of asthma, allergies and COPD al-
leviates the severity of sleep apnoea.
DIAGNOSISOF SLEEPAPNOEA
Diagnosis of sleep apnoea
When sleep apnoea is suspected, the ¢rst thing to do is
to establish whether the patient’s symptoms indicate
sleep apnoea andwhether further evaluation of this diag-
nosis is of primary importance. The patient may su¡er
from another illness causing fatigue or health hazards,
the further evaluations of which shouldbe initiated prior
to or simultaneously with the evaluation for sleep ap-
noea. At the second phase, the objective is to con¢rm
or exclude sleep apnoea and evaluate the severity of the
diagnosed illness. The phases of sleep apnoea diagnosis
are shown in Fig. 5, with more details inTable13 and Ap-
pendixes 2, 4^8.
Basic evaluations: establishing sleep apnoea
suspicion and the riskof sleep apnoea
Themost important tool in the evaluation is the record-
ingof patienthistoryusing a questionnaire on symptoms.The illness develops slowly, and the patientmay consider
the symptoms to bepart of his personality without iden-
tifying them.A sleepiness questionnaire is used to collect
information on the severity of the symptoms (e.g. ES-
S=Epworth Sleepiness Scale, Appendix 2).Central symp-
toms, risks and concomitant illnesses are established
when recording the history and, in connection with a
physical examination, attention is paid to the general ap-
pearance, body mass index (BMI) (Appendix 4) and the
blood pressure of the patient, as well as nasal, pharyn-
geal and facial structure (Table13).
If the symptoms, ¢ndings and risk factors primarily
suggest (1) health problems other than sleep apnoea (de-
pression, hypothyroidism, diabetes) or (2) risk factors of
sleep apnoea or, atmost, mild sleep apnoea, further eva-
luations, symptoms follow-up, health education and pa-
tient guidance in accordance with the problem will be
implemented within primary health care. Should the
¢ndings suggest moderate or severe sleep apnoea,
further evaluations will be performed in specialist care.
Appendix 5 shows a checklist for a GP/occupational
healthphysician for referrals to sleep apnoea evaluations.
The referral will be directed in accordancewith the allo-
cated duties to an outpatient unit specialising in sleep
evaluation, most often an outpatient department of pul-
monary diseases at present.
Specialist evaluations anddiagnostic
methods
If an obese patient has typical indications of sleep ap-
noea, the diagnosis is primarilymade on thebasis of sleep
registration.The need for other examinations is de¢ned
individually. As a general rule, sleep apnoea evaluations
are complemented by an ENT specialist consultation.
This is necessary in order to ¢nd the patientswhowould
bene¢t from surgical treatment.Thepurpose of the con-
sultation is also to assure nasal breathing with regard to
potential CPAP treatment. If the structural deviations of
the face are distinct, evaluations by a maxillofacial sur-
geon and a specialist in orthodontics on the deviations
are included. Appendix 6 lists examples of situations
whenconsultationwith a specialist fromoutside the spe-
cialty concerned should be considered. Diagnostic eva-
luations of patients under 15 years of age are arranged
by paediatric units.For patients under 2 years of age, ex-
tensive sleep registration is always recommended.Table
14 shows the specialist tools for the evaluation of sleep
apnoea.
Limited sleep registration monitors airways patency,
respiratory resistance, movements of the chest and legs
and changes in oxygen saturationmeasuredbypulseoxy-
meter expressed asODI (¢gure describing falls in oxygen
saturation during sleep). Extensive sleep registration is
the most expensive form of sleep registration. Apart
SUSPECTED SLEEP APNOEA
- The person personally suspects that he has symptoms of sleep apnoea
- Health check reveals history or constitution suggestive of sleep apnoea
- The attending doctor or dentist is alerted by suspicion of sleep apnoea
in connection with other treatment
EVALUATIONS WITHIN PRIMARY AND OCCUPATIONAL HEALTH CARE
- Mapping of symptoms
- Mapping of risk factors
- Establishing the use of alcohol, drugs and smoking
- Physical examination
- Laboratory and x-ray examinations
EVALUATIONS WITHIN SPECIALIST HEALTH CARE
- Complementary history and physical examination by a specialist
- Sleep recording (limited/extensive if needed)
- Complementary laboratory and x-ray examinations
- Consultation of an ENT specialist
- Consultation of an oral and maxillofacial surgeon and an orthodontist
- Other consultations as necessary
- Differential diagnosis
FIG 5. Diagnosis of sleep apnoea.
SLEEPAPNOEA 345from other changes during sleep, it is used to monitor
the di¡erent phases of sleep with the help of electroen-
cephalography (EEG) (Appendix 7). Extensive evaluation
is necessary in special cases even though the diagnosis
can normally be con¢rmed by limited sleep registration
(Table 15). The unit performing the evaluation gives a
clear report on the results, including information about
the diagnostic methods as well as the quantitative re-
sults. Being able to relate the results from the registra-
tion to the symptoms of the patient is necessary.
Di¡erential diagnostics
Daytime fatigue alsohas causes other than sleep apnoea.
With regard to di¡erential diagnosis, the most common
causes of daytime fatigue are listed inTable16.
Alternatives for the di¡erential diagnosis of sleep ap-
noea in children are shown inTable17.CHAINOF TREATMENT
Patients with sleep apnoea are encountered at all levels
of the health-care chain both in primary and occupa-
tional health care and in specialist health care (Table18).
Theprevention, treatment andrehabilitation of sleep ap-
noea include many tasks that are implemented outside
the health centre and hospital system. Patient organisa-
tionshave a central role, but themunicipal social services
and exercise departments as well as the private sector
participate in o¡ering services suitable for patients with
sleep apnoea. The prevention, treatment and follow-up
of sleep apnoea are a joint e¡ort of all these sectors.
The tasks of primary health care are theprevention of
sleep apnoea, the treatment of patients with mild-to-
moderate sleep apnoea as agreed in cooperation with
specialist health care, and the treatment of concomitant
illnesses.The tasks of specialist health care are con¢rm-
ing the sleep apnoea diagnosis, drafting a plan for the
treatment and rehabilitation of the illness, initiating
TABLE 13. Tools of primary and occupationalhealth care forcon¢rming sleep apnoea suspicion
Tools Symptoms and ¢ndings indicative of sleep apnoea
1.Historyof symptoms  Symptomswhile awake
 Symptomswhile asleep
2.Knowledge of risk factors  Beingmale
 Beingmiddle aged orpostmenopausal
 Weightgain
 Allergic rhinitis
 Otherconcomitant illnesses
 Snoring
3.Historyof intoxicantuse  Use of alcohol
 Use of CNS depressants
 Smoking
4.Questionnaire on symptoms  E.g.ESS (Appendix 2)
5.Bodymass index (BMI)  Appendix 4
6.General status  Central obesity and thickness of neck
 Signs of other predisposing illnesses, such as
 hypothyroidism, arthritis, acromegaly,
 kyphoscoliosis
7. Anatomyofthe upper respiratory tract  Anatomicallynarrownose
 Polyps
 Large tongue
 Long soft palate, large uvula
8.Jaw and face  Small jaws, maxillaryormandibular retrusion
 Domedpro¢le
 Longlower face
 Deviatingocclusion
9.X-ray and laboratory tests  Appendix 5
346 RESPIRATORYMEDICINECPAP treatment, implementing other specialist health-
caremeasures and supporting primary health care in im-
plementing further treatment and follow-up as agreed.
The instruments designed for the diagnosis and treat-
ment of sleep apnoea have become simpler. With sup-
port from specialist health care, it is possible to screen
the patients with sleep apnoea primarily within primary
health care.Problematic cases shouldbe referred to spe-
cialist treatment. A self-regulating CPAP device adjusts
the pressure level automatically to comply with the pa-
tient’s needs, rendering admissions to hospital for pres-
sure titrations redundant. The device records deviating
respiratory events and the actual duration of use.
As the number of sleep apnoea patients receiving
treatment increases, the taskofmonitoring sleep apnoea
will be increasingly directed to primary health care with
specialist consultations inproblematic caseswhenneces-sary. Active treatment chains require (1) agreement be-
tween the di¡erent levels of health care, (2) education of
primary health care and (3) research.
The treatmentchain and the treatment lines shouldbe
adjusted regionally due to varying patient numbers, ar-
rangements for cooperation and treatment opportu-
nities. Appendix 9 shows an example of the treatment
lines within primary health care.
TREATMENT
Goals andmethods
The aim of the treatment of sleep apnoea is to eliminate
the respiratory interruptions. If this succeeds, the treat-
ment is curative. Even if the respiratory interruptions
are not entirely eliminated, they can be controlled by
TABLE 14. Tools of specialisedhealth care forcon¢rming sleep apnoea
Basic evaluations in specialisedhealth care
 Patienthistory and clinical examination
 Consulting other specialties on a case-by-case basis
 Sleep registration (limited orextensive, if needed)
 Symptomquestionnaires
Furtherevaluations (whenneeded)
 Flow volume spirometry
 Arterial blood oxygen saturation
 Complementary X-ray and laboratory tests
 Cephalometric sleep apnoea X-rayevaluation
 Nasal function evaluations
 Fibroscopyofthe upper respiratory tract
Special tests for evaluating the patient’sworkingand functional ability
 Multiple sleep latency test (MSLT)
 Maintenance of wakefulness test (MWT)
 Driving simulationtest
TABLE 15. Symptoms and ¢ndings a¡ecting the choice of sleep registrationmethods
 Highlyprobable sleep apnoea onthe basis of symptoms and ¢ndings
-; limited sleep registration oronenightwith a self-regulating CPAP device and oxymeter
 Snoringpatient lacking other symptoms suggesting sleep apnoea
- limited sleep registration (upon consideration)
 Probable sleep apnoea onthe basis of symptoms and ¢ndings
- limited sleep registration
 Possiblyother than sleep apnoea, atypical symptoms and ¢ndings
- extensive sleep registration
 Results fromextensive sleep registration are unclear, orno treatmentresults are reached despite good treatmentcompliance
-extensive sleep registration
SLEEPAPNOEA 347various treatment methods so that the patient feels
cured. It can also be presumed that the risks deriving
from an untreated illness are avoided.Table19 shows the
goals of the treatment of sleep apnoea. A summary of
the di¡erent treatment methods is presented in Table
20. Central factors in choosing the mode of treatment
are the cause of the respiratory obstruction and the se-
verity of the disease.
Conservative treatment
Weight reduction and weight control
Weight reduction as a treatment of sleep apnoea is of
primary importance for all obese patients with sleep ap-
noea. A treatment programme for obesity is initiated if
the patient is at least signi¢cantly overweight (BMI
Z30kg/m2). In the range of slight overweight (BMI 25^
29.9 kg/m2), weight reduction is necessary if the patientsu¡ers from central obesity (waist circumference
490 cm inwomen and4100 cm inmen).
The objective of the treatment in adults is permanent
weight loss of 5^10%.The targetweightdoes notneed to
be the normal weight, which is usually an unrealistic ob-
jective for severely obesepatients.Obesepeople tend to
continue gaining weight and, particularly in cases of
slight overweight, arresting the accumulation of weight
is already a signi¢cant initial result. The treatment of
obesity is mainly implemented within primary health
care. Severe, pathological obesity that is associatedwith
sleep apnoea and requires weight reduction can be trea-
tedwithin specialist care.
Weight control after weight reduction requires per-
manently lowered energy intake and/or greater energy
consumption than prior to the weight reduction. The
treatment of obesity includes expert guidance in perma-
nent life-style changes. The Medical Society Duodecim
has published a consensus treatment recommendation
TABLE 16. Other conditions thatcan cause daytime
fatigue
Sleep disorders
 Insu⁄cient sleep
 Insomnia
 Restless legs
 Narcolepsy^cataplexy
 Sleep^waking schedule disorders
 Chronic fatigue syndrome
 Idiopathic hypersomnia
 Psychiatric reasons
 Otherdisorders
Other illnesses
 Depression (Appendix 8)
 Hypothyroidism
 Anaemia
 Diabetes
 Epilepsy
 Cerebral disorders
 Musculardisorders
 Dementia
 Adverse e¡ects ofmedical treatment
 Pulmonaryhypoxia
 Chronic infections
 Vasculitis
TABLE 17. Alternatives fordi¡erential diagnosis of sleep
apnoea in children
 Stenosis of the airways
 Laryngomalacia
 Asthma
 Gastro-oesophagealre£ux
 Nocturnal epileptic seizures
 Restless legs
 Narcolepsy
 Central sleep apnoea
348 RESPIRATORYMEDICINEfor adult obesity in 2002.Table 21showsmethods for the
treatment of obesity. Appendix10 describes the content
of basic care and brief guidance.
Position therapy
Most patients snore less when they lie on their side. At-
taching a tennis ball to the back of the nightgown may
prevent supine sleeping, or various cushions or supports
can be placed under the back. Position treatment can
help patients with mild sleep apnoea but motivating pa-
tients to adopt this mode of treatment is problematic.The long-term bene¢ts of this treatment have not been
established.
Medicines
Several di¡erent medicines have been used in the treat-
mentof sleep apnoea but, in repeated controlled studies,
none of them has proved more e⁄cient than placebo.
Progesterone derivatives have yielded the best results.
Newmedicines are being developed, but their introduc-
tion to themarketmay take years. Sleep apnoea may be
associated with depression, which must be treated ap-
propriately using modern antidepressants. If sleep
apnoea is associatedwith severe obesity, pharmacother-
apy may be considered. There are two medicines, orlis-
tate and sibutramide, for this. If the patient su¡ers from
moderate-to-severe sleep apnoea, his BMI is432kg/m2
and a loss of weight of at least 4 kg has been reached
prior to the initiation of pharmacotherapy in an 8-week
dieting programme, the Social Insurance Institution can
grant basic reimbursability for an anorexigenic medicine
on the basis of Medical Statement B.
Devices in£uencing the position ofthe mandible and the
tongue, and orthodontic treatment
There are various devices in£uencing the position of the
tongue and themandible.Devices preventing the retrac-
tion of the tongue or devices that protrude themandible
can be placed in the mouth. These devices help prevent
snoring in particular. The device may present a solution
for patients with problematic snoring without elevated
apnoea indices, and for patients with mild sleep apnoea.
The bene¢ts of the device are evaluated by sleep regis-
tration.
Orthodontic treatment plays a role in the prevention
of sleep apnoea in children. In adults, orthodontic treat-
ment is an essential part of the surgical treatment of the
mandible.
Continuous positive airway pressure treatment
Theprinciple of CPAP treatment is to create positive air-
way pressure, an ‘‘air splint’’, using a nasal mask and an
air-blowing device, thereby counteracting the collapse
of the airways. It in£uences thewideningof theupper re-
spiratory tract also indirectly by increasing the residual
volume of the lungs.
CPAP treatment can be o¡ered to patients with diag-
nosed sleep apnoea.CPAP treatment has been found to
correct respiratory disturbances during sleep. It is the
primary mode of treatment in severe sleep apnoea and
in some cases ofmoderate sleep apnoea, keeping the im-
portance of weight control in mind. The indications of
CPAP treatment are shown inTable 22.There are no ac-
tual contraindications to CPAP treatment, but not all
TABLE 18. Treatmentchain of a patientwith sleep apnoea
Tasks of primaryhealth care:
1.Prevention
2.Con¢rmingand treatingproblemsin occlusion andmaxillomandibular position
3.Con¢rming suspected sleep apnoea, basicevaluations, andreferring the patientto specialisedhealth care for further examina-
tions
4.Treatment and follow-up ofmild-to-moderate sleep apnoea as agreed
5.Basic treatmentof obesity and brief instruction (mini-intervention)
6.Treatmentof concomitant illnesses
7.Providingdevices services in compliancewith provincial collaborationprocedures
8.O¡ering guidance inmatters relating to illness and social security
9.Organising rehabilitation services
Tasks of units providing specialised health services
1.Con¢rming sleep apnoea diagnosis
2.Drafting and implementing treatment andrehabilitationplans
3.Designing, adapting and initiatingdevice treatment
4.Deliveringdevices, o¡ering guidance and organising adaptationtherapy
5.Monitoring the status of bothpatient and instruments in collaborationwith primaryhealth care
6.Surgicalprocedures
7.Treatmentof extreme or severe obesity
8.Comprehensive evaluation of workingability, and evaluation ofthe need foroccupationalrehabilitation
9.Diagnosis, treatment and follow-up of problematic cases
10.Designingprovincial treatmentchains and developing the qualityof services in collaborationwith primaryhealth care
Tasks of other service providers
1.Organisingrehabilitation services (SII, associations andrehabilitation institutes)
2. Supporting the patient’s social skills, organisinghealth education (associations)
3.Supportingweight reduction andweightcontrol (associations, pharmacies)
4.Promoting exercise (associations, municipalities)
5.Promotinga supportperson system (associations)
6.Device development (business life)
TABLE 19. Objectives for the treatmentof sleep apnoea
 Curing sleep apnoea
 Maintainingworkingand functional ability
 Improving the qualityof life
 Preventingand treating concomitant illnesses
 Preventing the aggravation of sleep apnoea
SLEEPAPNOEA 349patients adapt to the treatment. Some conditions cause
more problems than usual in connection with CPAP
treatment and can be considered relative contraindica-
tions (Table 23).
In order for CPAP treatment to be e¡ective, it should
be used at least ¢ve nights a week, 3^4h/night. The
treatment does not cure the illness. CPAP treatment is
initiated at a health-care unit with su⁄cient facilities.
Once the correct pressure level (usually 5^15 cmH2O)
has been attained, sleep is usually normal and thereshould no longer be any abnormal arousals. After the in-
itiation, the patient takes the device home for a trial of a
few weeks, after which the treatment success is evalu-
ated.Once the CPAP treatment has been successfully in-
itiated and the patient has been instructed in the use of
the device, the treatment canbemonitored on an annual
basis. Follow-up visits may be arranged as appointments
with a nurse or a rehabilitation instructor trained for
the follow-up. The treatment device will be inspected
and serviced at the follow-up visits. Should it be found
during the follow-up visit that the overall situation of
the patient has changed or the patient has other health
problems, he will be referred to a doctor. The aim is to
arrange the follow-up preferably within primary health
care.
Over 90% of the sleep apnoea patients using theCPAP
device feel that they have obtained bene¢t from the
treatment. Most adverse e¡ects of CPAP treatment are
minor. Problems arise in 30^50% of the patients, but
they do not usually result in the discontinuation of the
treatment if the patient feels that the symptoms have
TABLE 20. Treatmentmethods of sleep apnoea
Methods for the treatment ofmild sleep apnoea
 Weightreduction andweightcontrol
 Medical treatment improvingnasal breathing
 Surgical treatment improvingnasal breathing
 Devices a¡ecting the position ofthe tongue and themandible
 Discontinuing smoking
 Refraining fromthe use of CNS depressants andparticularly sleepingmedicines
 Positiontherapy
 Good treatmentof concomitant illnesses
Additionalmethods for the treatment ofmoderate-to-severe sleep apnoea
 Hyperbaric breathing throughthe nose (nasal CPAP)
 Oral andmaxillofacial surgery
 Uvulopalatopharyngoplasty
 Treatmentof obesitywithmedicines and operations
 Tracheostomy
All patients with sleep apnoea
 Adaptationtherapy andrehabilitation
TABLE 21. Methods for the treatmentof obesity
Method When can it be used?
Brief instruction (mini-intervention) As awayofmotivating the patientorwhenbasic treatment
cannot be provided
Basic treatment of obesityGuidance in
changing thewayof life,10^20 visits,
usually in groups
Primaryoptionused in connectionwith all othermethods.Suitable for all.
Extremelylow-calorie diet in connection with
basic treatment
Generally when BMIisZ 35 kg/m2.Optionalwhen BMIis
30^34.9 kg/m2 Onlyexceptionally when BMIis 25^29.9 kg/m2
and basic treatmenthas failed
Anorexigenic medicines (orlistate, sibutramine) Basic treatmenthas failed and BMIisZ 30 kg/m2
Surgical treatment For selected and treatment-compliant patientswhen BMI
isZ40 kg/m2 and other treatmentmethodshave failed
350 RESPIRATORYMEDICINEalleviated. The commonest problems are due to irrita-
tion of the nasal mucosa. Severe adverse e¡ects relating
toCPAP treatment are quite rare.Theproblems ofCPAP
treatment and the treatments of CPAP-related nasal
symptoms are described inTables 24 and 25.
Poor treatment compliance is predicted by
previous corrective surgery of the pharynx and
a mild illness with few symptoms. If the patient does not
adapt to CPAP treatment, it is important to make surethat other forms of treatment and follow-up will con-
tinue.
Surgicalmodes of treatment
The objective of surgical treatment of sleep apnoea is to
widen the airways by surgery.The surgery can be direc-
ted to soft tissue or to bony structures.The airways are
TABLE 22. Indications of CPAP treatment
 Experimental treatment for allpatientswith AHI430 regardless of symptoms a
 If AHIis 5^30, treatment is initiated if the patienthas disturbing symptoms or ¢ndings:
* Abnormal daytime fatigue and tendency to doze o¡
* Cognitive disorders
* Recurrent awakenings
* Severe cardiovasculardiseases
* Mood changes
aIf the patient is over 70 years of age, treatment is initiated individuallydepending onthe symptoms.
TABLE 23. Possible contraindications to CPAP treatment
 Floppyepiglottis
 Chronic or acute in£ammation ofthe upper respiratory tract
 Completelyblockednose, problematic nasalpolyposis
 Otitis
 Air accumulation in the stomach inpatientswith diaphragmatic hernia
 Severe alcoholism
 Problematic untreatedpsychiatric illness
TABLE 24. Problems of CPAP treatment
 Drying and encrustation of nasal, oral and pharyngeal
mucosa
 Persistent rhinorrhoea andrecurrent sneezing
 Nasal congestion
 Recurrentepistaxis
 Skin irritationunder themask
 Irritation oftunica conjunctiva
 General discomfortcaused by the treatment
 Undetectedpsychiatricdisorder
 Poor treatmentcompliance
TABLE 25. Treatmentof CPAP-relatednasal symptoms
Prevention ofthe dryingofnasalmucosacausedbyrecycledair:
 Optimalpressure level
 Facialmask that ¢ts aswell as possible
 Support for the jaw
 Nasal^oralmask
 Humidi¢er
Symptom-dependent treatment:
 Vasoconstrictors (for temporaryuse only)
 Humidifying solutions
 Local steroids
 Ipratropiumbromide
SLEEPAPNOEA 351widenedby the removal of an isolatedobstructive factor,
such as large tonsils or nasal polyps.The pharynx can be
widenedby the removal of the surrounding tissues, which
is a secondarymethodwithregard toCPAP treatment, or
by changing the relative locations of the tissues by maxil-
lomandibular osteotomies. Since scienti¢c evidence on
theusefulness of the surgical treatments is still partly con-
tradictory, more studies are needed. Surgical treatment
methods and their e¡ects are shown inTable 26.
REHABILITATIONANDDEVICES
Rehabilitation
In the rehabilitation of a patient with sleep apnoea, the
primary focus must be on directing the patient towardself-care and encouraging him to adopt it. Exercise,
weight loss, weight control, abstinence from smoking,
and prevention of the overuse of alcohol are essential
features of self-rehabilitation. As a general rule, rehabili-
tation should be organised as outpatient rehabilitation in
connectionwith primary health care.
Medical rehabilitation includes o¡ering advice about
rehabilitation and available rehabilitation services, evalu-
ating the patient’s need for rehabilitation and the di¡er-
ent rehabilitation options on the basis of the patient’s
working and functioning capacity, occupational rehabili-
tation, physiotherapy and other similar therapies,
TABLE 26. Surgicalmodes of treatment
Site of
operation
Procedure E¡ectof procedure
Nose  Straightening of a deviatednasal septum -Decreases the airwayresistance, caused
by the deviated septum
 Reduction ofthe size of nasal concha -Increases the space in the nasalmeatus
 Removal of polyps -Increases the space in the nasalmeatus
 Correctional surgeryof external
nasal structure
-Decreases the obstruction caused
byexternalnasal structure
-All forms of nasal correctional surgerycan improve
the success of CPAP treatment
Adenoid tissue  Removal of adenoids -Widens the oropharynx
 Removal of tonsils -Widens the nasopharynx
Palate  Uvulopalatopharyngoplasty -Removal of obstructive softtissue ofthe pharynx
to preventthe collapse ofthe tissue
Mouth and jaw  Genioglossalmuscle advancement
(GGA surgeryofthemandible)
-Increases the air space behind the tongue
 Bilateral sagittal splitosteotomy (BSSO) -Advances the tongue andwidens the pharynx
 Maxillomandibular advancement (MMA) -Increases the air space (maxillary advancement
enables su⁄cientmandibular advancement)
Trachea Tracheostomy -Passages obstructing the pharynx are bypassed
352 RESPIRATORYMEDICINEadaptation therapy, device services, and rehabilitation
guidance. These methods can be used either in outpati-
ent care or during institutional rehabilitation periods.
Adaptation therapy involves guiding the patient and
his family in postdiagnostic lifemanagement. Adaptation
therapy is usually group therapy. In most cases, specia-
lised health-care units responsible for the treatment of
sleep apnoea organise survival course-like adaptation
therapy, for which they select the patients. The health-
care units plan and organise the courses either by them-
selves or in collaboration with other organisations. Hav-
ing the patient’s family attend the courses is considered
essential as regards the successful rehabilitation of the
patient. Rehabilitation institutes o¡er adaptation ther-
apy courses as well. Patients with a payment agreement
from specialised or primary health care canbe accepted,
but patients usually apply for the courses through the
Social Insurance Institution on the basis of the treating
physician’s statement.
The main task of the Social Insurance Institution is to
organise the rehabilitation of severely handicapped pa-
tients. SII also organises other forms of individual rehabi-
litation and courses, for which patients are selected on
the basis of the treating physician’s medical statement B
within annual resource limits. In 2000, SII funded the re-
habilitation of 219 patients with sleep apnoea.Of these,
123 were in working life and received a rehabilitation al-
lowance from the Social Insurance Institution.
If a patientwith sleep apnoeaworks in tra⁄c or in an-
other profession requiring exceptional alertness andprecision, and if the treatment is not successful in elimi-
nating all his symptoms, means of occupational rehabili-
tation can be considered. The objective is to ¢nd a
suitable job for the patient, thus allowing him to partici-
pate fully inworking life.The services of occupational re-
habilitation are vocational guidance, rehabilitation
research, experiments with work and training, pre-
work training, on-the-job training, ¢nancial support, de-
vices, and renovations to the workplace. Occupational
rehabilitation also includes training subsidy.The Social In-
surance Institution is under an obligation to organise oc-
cupational rehabilitation unless it is arranged through
employment pension legislation or employment initia-
tives.
Device services
The positive airway pressure device (CPAP device) used
in the treatment of sleep apnoea is a medical device
which falls under theAct and theDecree onMedicalRe-
habilitation, and the sections on devices in the Act on
Public Health and the Act on Specialised Health Care.
Device services include evaluating the patient’s need for
devices, adapting the device for the individual patient and
delivering it for either temporary or permanent use,
teaching the patient to use it, monitoring its use, and
maintaining it inworking order.
Theunitdelivering the device is responsible forprovid-
ing thepatientwith su⁄cient instructions on its use.The
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safe. In practice, the unit either arranges regularmainte-
nance of the device, or purchases the service elsewhere.
This is possible only when the device register is func-
tional.
The Finnish Lung Health Association has colla-
borated with two hospital districts over the design
of a respiratory device register, which could be
developed into a functional system for wider use. Ac-
cording to existing legislation, a health care unit cannot
leaveresponsibility fordevicemaintenance to thepatient
alone.
Apart from the actual device, the CPAP treatment
package includes a mask, headgear, and tubes. Supplies
for the use of patients with sleep apnoea are distributed
only by specialised health care, since selecting the sup-
plies, training the patients, and monitoring the use of
the device demand specialised expertise.
In the near future, primary health care may be as-
signedgreater responsibility for providingdevice services
according to a local agreement.The importance of other
organisations in providing device services may also in-
crease in the future.
SOCIALSECURITY
The social security of patientswith sleep apnoea is based
on the basic Finnish social security system. Devices for
the treatment of sleep apnoea are lent to the patient
(see paragraph ‘‘Medicines’’). The patient can apply to
the Social Insurance Institution, for example, for
reimbursement of treatment and medical costs,
disability allowance, and care allowance. If the patient is
unable to work, he can apply to the Social Insurance In-
stitution for sickness allowance, and either to the Social
Insurance Institution or to the patient’s employment
pension institution for disability pension.The patient can
apply to the municipal social sector for services de¢ned
in theActon Services forDisabled Persons.There areno
speci¢c decrees concerning this patient group, with the
exception of the reimbursability of anorexigenic
medicines on certain conditions (see paragraph ‘‘Device
Services’’).
COSTS
American studies have indicated thatuntreated sleep ap-
noea nearly doubled theuse of health services compared
to the control population.On the other hand, successful
and motivating treatment of sleep apnoea signi¢cantly
decreased the use of health services compared to the si-
tuation prior to treatment.Comparable studies have not
been conducted in Finland.
There are no exact calculations of the costs of treat-
ment for sleep apnoea. The costs can be estimated byproportioning the number of patients to the known
average prices of the services.The price of an individual
patient’s treatment can be estimated on the basis of the
prices of di¡erent procedures and treatments suitable
formostpatients (Appendix11).Realistic treatmentcosts
are represented by the calculations made in the Varsi-
nais^Suomi hospital district, which indicate that the di-
rect annual costs of the diagnosis and the treatment of
sleep apnoea amount to more than1.68 million euros in
this hospital district alone.
The treatment costs of patients with mild sleep ap-
noea can consist of, for example, doctor’s fees and la-
boratory tests in primary health care, and participation
inweight loss groups and exercise groups.The treatment
of such patients amounts to approx. 151A in the initial
phase, and further expenses are approx. 101A per an-
num. Patients in the specialised health-care sector are
usually patients on CPAP treatment. The CPAP treat-
ment of each new sleep apnoea patient costs approx.
1682h in the ¢rst year, after which the annual costs of
successful treatment amount to approx. 252h. In prac-
tice, 5 years of CPAP treatmentcost approx. 2691h. After
the 5-year period, the costs includenotonly annualmon-
itoring but also the replacement of the device. Recent
trends suggest that if 1000 new patients require treat-
ment every year, and if 4000 previously treated patients
aremonitored at the same time, as indicated by the sta-
tistics from 1998, 2.7 million euros are spent on CPAP
treatment per annum, not counting the costs of device
replacement. In1998,1000 CPAP devices passed their re-
commendedusage age of 5 years,which added 0.5million
euros to the expenses. The calculations do not account
for the treatment of problematic patients requiring spe-
cial examinations that also add to the expenses.
Half of the sleep apnoea patients under 65 years of age
onCPAP treatment are inworking life. If thepatientdoes
not su¡er from other illnesses, sleep apnoea alone is not
a common cause of incapacity for work.No statistics are
available for sick leaves or pensions accordedon thebasis
of diagnosed sleep apnoea.
IMPLEMENTATIONOF THE
PROGRAMME
Information, training and guidance
The implementation of the sleep apnoea programme
calls for the distribution of information, education of
key groups, and continuous guidance.Key groups include
peoplewho are at a high risk of developing sleep apnoea,
those with sleep apnoea, and those directly involved in
the treatment of sleep apnoea. Key groups also include
people who can actively help prevent sleep apnoea in
their work (planners, product designers), peoplewho in-
form others of issues concerning health and illness
(reporters, representatives of organisations, and manu-
354 RESPIRATORYMEDICINEfacturers of devices), and peoplewho are in a position to
decide how public resources are used.
The responsibility for distributing information and
educating keygroups canbe shared so that organisations
such as the Finnish Lung Health Association, the Pul-
monary Association HELI and the Finnish Sleep Apnoea
Association are responsible for informing their own
members and, in part, the general public.Together with
experts, the organisations produce material needed in
patient education.To this end, organisations can receive
funding from the Finnish Slot Machine Association, for
example. The Social Insurance Institution distributes in-
formation on social security and the ways in which the
SII supports the patient’s capacity for work.The authori-
ties are responsible for informing experts and training
them in collaborationwith di¡erent associations and so-
cieties.These include theMunicipalDoctorsAssociation,
the Orthodontic section of the Finnish Dental Society
Apollonia, the Finnish Dental Association, the Associa-
tion of Finnish Pulmonary Physicians, the Finnish Society
ofClinical Physiology, the Finnish SocietyofClinicalNeu-
rology, the Association of Finnish Otolaryngologists, the
Finnish Paediatric Association, the Finnish Neurological
Society, the Finnish Federation of Nurses, the Finnish In-
ternal Medicine Association, the Finnish Sleep Research
Society, the FinnishAssociation forGeneral Practice, the
Association of Oral and Maxillofacial Surgery, the Union
of Health and Social Care Professionals, the Association
of Health Centre Dentists and the Finnish Sleep Federa-
tion. Provincial guidance and education will be the joint
responsibility of hospital districts and provincial govern-
ments, whereas health centreswill be responsible for lo-
cal guidance andeducation.Themedia have an importantTABLE 27. Information and trainingneeded for the implementa
Information and education
Initial distribution of information
and informingkeygroups
Nationalnegotiations, education and support
National sleep apnoea days
Provincial education
Local education
Informing the generalpublicopportunity to initiate debate on the programme and to
support its goals and principles (Table 27).
Special attention must be paid to the training of new
health-care professionals.The fundamental principles of
the sleep apnoea programme should be included in the
curriculum of health-care institutes, medical faculties,
and specialist training programmes. The possible need
to train experts in sleep apnoea, such as respiratory
nurses, sleep technicians andweight loss programme lea-
ders, for practical work should be considered in the im-
plementation of the programme. Hospital districts
should prepare collaborative programmes for the pre-
vention and treatment of sleep apnoea to be applied lo-
cally. Hospitals have reported positive experiences of
regular meetings of working groups on sleep attended
by representatives of the appropriate specialised
branches. The revision of the treatment recommenda-
tions canbe accomplishedbypreparing aDuodecim con-
sensus treatmentrecommendation after theprogramme
has been launched.
Research andmonitoring
Universities, health-care institutes, health-care associa-
tions and individualresearchershave conductedresearch
into sleep apnoea in Finland. In Health 2000 survey, a
comprehensive studyby theNational Public Health Insti-
tute, the sleep of the populationwas one of the subjects
studied. In future, the study can be used in the monitor-
ing of the programme. However, more population stu-
dies on the prevalence and signi¢cance of the illness are
needed. Studies on the mechanism of sleep apnoea, thetion ofthe programme
Theresponsible authority
Finnish Lung Health Association,Pulmonary Association
HELI,Finnish Sleep Apnoea Association
Finnish Lung Health Association,Finnish Sleep Federation
and otherorganisations
Associations ofmedical specialists, di¡erent societies
Hospital districts, provincial governments, provincial
occupationalhealth organisations, societies
Health centres, occupationalhealth care, societies
Media, societies, experts
TABLE 28. Developmentneeds for the research andmonitoringof the sleep apnoea programme
 Prevalence and incidence of sleep apnoea
 Earlydiagnosis and treatment
 The signi¢cance of risk factors and concomitant illnesses to the incidence of sleep apnoea
 The signi¢cance of childhoodmalocclusions and enlarged tonsils and adenoids to the incidence of sleep apnoea
 The e¡ectof treatment andrehabilitation on costs
 Creating comprehensive follow-up systems
SLEEPAPNOEA 355risk factors, themethods of treatment and their cost-ef-
fectiveness are also needed. Table 28 lists the develop-
ment needs for the research and monitoring of the
sleep apnoea programme. Joint meetings/seminars of
sleep apnoea researchers should be arranged annually.
Creating a well-designed, functional and continuous
system of quality control and direction is necessary for
the implementation of the programme. Special attention
must be paid to the monitoring of the success of sleep
apnoea prevention and treatment. Existing registers of
respiratory devices and material withdrawn from use
should be developed for use in the monitoring of treat-
ment success and patient £ow.The system ofmonitoring
overweight people at a high risk of developing sleep ap-
noea should be developed so that the treatment of the
illness can be initiated early on. The provincial applica-
tions of the sleep apnoea programme should includeme-
chanisms for monitoring the implementation of the
provincial programmes. The Finnish Lung Health Asso-
ciation appoints amonitoring group to support and eval-
uate the implementation of the sleep apnoea
programme. A more comprehensive follow-up report
and evaluationwillbemade once the ¢rst-half of the pro-
gramme has been completed.
Costs of the programme
The costs of the programme for the prevention and
treatment of sleep apnoea mainly consist of communica-
tions, training and programmes for quality control and
direction. These are not additional expenses, but ex-
penses relating to thenormal functions and development
of health-care units and associations. The communica-
tions, training, production of material and development
of strategic forms of operation relating to the launch of
the programme should receive ¢nancial support from
health-care development funds (e.g. from the Finnish
Slot Machine Association). The additional expenses of
the launch of the programme (training, communications,
guidance, monitoring) amount to under one million
euros in 2002^2006.
If the programme is implemented and the quality of
the prevention and treatment of sleep apnoea is im-proved, sleep apnoea can be treated with the best
possible cost-e¡ect ratio. If the programme is not imple-
mented, the costs caused by sleep apnoea, which has
proved to be a national health problem in Finland, will
increase signi¢cantly.
SUMMARY
(1) After negotiations with the Finnish Ministry of Social
A¡airs and Health, a national programme to
promote prevention, treatment and rehabilitation of
sleep apnoea for the years 2002^2012 has been
prepared by the Finnish Lung Health Association on
the basis of extensive collaboration.The programme
needs to be revised as necessary, because of the
rapid development in medical knowledge, and in
appliance therapy in particular.
(2) Sleep apnoea deteriorates slowly. Its typical features
are snoring, interruptions of breathing during sleep
and daytime tiredness. Sleep apnoea a¡ects roughly
3% ofmiddle-agedmen and 2% of women. In Finland,
there are approx. 150 000 sleep apnea patients, of
which 15 000 patients have a severe disease, 50 000
patients are moderate and 85 000 have a mild form
of the disease. Children are also a¡ected by sleep
apnea. A typical sleep apnea patient is a middle-aged
man or a postmenopausal woman.
(3) The obstruction of upper airways is essential in the
occurrence of sleep apnoea.The obstruction can be
caused by structural and/or functional factors. As
for structural factors, there are various methods of
intervention, such as to secure children’s nasal
respiration, to remove redundant soft tissue, as
well as to correct malocclusions. It is possible to
have an e¡ect on the functional factors by treating
well diseases predisposing to sleep apnoea, by
reducing smoking, the consumption of alcohol and
the use of medicines impairing the central nervous
system. The most important single risk factor for
sleep apnoea is obesity.
(4) Untreated sleep apnoea leads to an increase in
morbidity and mortality through heart and
circulatory diseases and through accidents caused
356 RESPIRATORYMEDICINEby tiredness. Untreated or undertreated sleep
apnoea deteriorates a person’s quality of life and
working capacity.
(5) The goals of the Programme for the prevention and
treatment of sleep apnoea are as follows: (1) to
decrease the incidence of sleep apnoea, (2) to
ensure that as many patients as possible with sleep
apnoea recover, (3) to maintain capacity for work
and functional capacity of patients with sleep
apnoea, (4) to reduce the percentage of patients
with severe sleep apnoea, (5) to decrease the
number of sleep apnoea patients requiring
hospitalisation and (6) to improve cost e¡ectiveness
of prevention and treatment of sleep apnoea.
(6) The followingmeans are suggested for achieving the
goals: (1) to promote prevention of obesity, weight
loss and weight control; (2) to promote securing of
nasal respiration in child patients and removal of
obstructing redundant soft tissues; (3) to promote
the correction of children’s malocclusions, (4) to
enhance knowledge about risk factors and
treatment of sleep apnoea in key groups, (5) to
promote early diagnosis and active treatment, (6) to
commence rehabilitation early and individually as a
part of treatment and (7) to encourage scienti¢c
research.
(7) On the national level, the occurrence of sleep
apnoea can be prevented, for example, by
encouraging weight control. The programme
gives examples of such measures and appeals to
various authorities and voluntary organisations to
reinforce their collaboration. Preventive measures
should be individualised, and based on due
consideration.
(8) The e⁄cacy of diagnosing sleep apnoea should be
increased. Attention should be paid to the
symptoms of risk group patients at di¡erent units of
the primary and occupational health care. Even mild
forms of the disease shouldbe treated appropriately.
Diagnosis and treatment of the disease involve
cooperation between the primary and specialised
health-care sectors. Methods of treatment are (1)
treatment of obesity, (2) positional therapy, (3)
reduction of the use of medicines impairing the
central nervous system, (4) reduction of smoking
and the consumption of alcohol, (5) devices
a¡ecting the position of the tongue and lower jaw,
(6) treatment with Continuous Positive Airway
Pressure (CPAP-treatment), (7) surgical methods of
treatment and 8) rehabilitation.
(9) The hierarchy of referrals in the prevention and
treatment of sleep apnoea should be revised to
accord a greater role to the primary health-care
sector. Good exchanges of information and
cooperation between the primary health care and
specialised medical-care sectors should bedeveloped. Hospitals districts in cooperation with
provincial governments and municipalities should
ensure that di¡erent levels of the health-care
system are capable of ful¢lling the tasks assigned to
them appropriately.
(10) Rehabilitation of sleep apnoea should be goal-
orientated and cover all forms of rehabilitation:
medical, occupational and social. Rehabilitation
should prevent the e¡ects caused by the disease.
Thus, it is possible to support self-care, increase
the patient’s resources and improve quality of life.
(11) Information and training should be directed
primarily towards health-care personnel, patients
and their families. Organisations should produce
materials for health and patient education as well as
organising training events.To support the activities,
¢nancing will be needed from organisations such as
Finland’s Slot Machine Association. The Social
Insurance Institution should disseminate
information about questions of social security.
Regional direction and training will mainly be the
responsibilities of hospital districts, provincial
governments and local health centres. The media
will play an important role in the dissemination in-
depth information about prevention and treatment
of sleep apnoea.
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SLEEPAPNOEA 359APPENDIX1:THEPHYSIOLOGYOFSLEEPANDTHEEVENTSDURINGAN
OBSTRUCTIVEAPNOEAEPISODE
Sleep is divided into two di¡erent stages, slow-wave andrapid eyemovement sleep (REM sleep) based on, for example,
EEG.Themuscle tone decreases during sleep.DuringREM sleep, themuscle tone isparticularly low, and the function of
respiratory muscles is the most vulnerable to disturbances. Apnoea is most easily caused by an obstruction in the
upper respiratory tract during REM sleep, after which the condition deteriorates at all stages of sleep and all sleeping
positions. Stimulated by the cerebral respiratory centre, the patient tries to breathe despite the obstruction in the
upper respiratory tract (=obstructive apnoea). Arousal causes an increase in the muscle tone, followed by strong
compensatory breathing. The sleep of the apnoea patient deepens, the muscle tone decreases and causes another
episode of apnoea, which is followed by a new arousal, recurrent episodes of apnoea, and disturbed sleep including
only short periods of deep sleep and REM sleep.The decrease in oxygen saturation (SpO2) as measured by pulse oxy-
meter from the ¢nger occurs approx.15 s after the episode of apnoea.
APPENDIX2:SLEEPINESSQUESTIONNAIRE[EPWORTHSLEEPINESSSCALE(ESS)]
Abnormal sleepiness is indicated if the ESS score is410.
(This informationmust not be visible in the form given to the patient)
Instructions:How likely areyou to doze o¡ or fall asleep in the following situations, in contrast to feeling just tired? This
refers toyourusualwayof life inrecent times.Evenif youhavenotdone some of these thingsrecently try toworkouthow
they wouldhave a¡ected you.Use the following scale to choose themost appropriate number for each situation:
Scale (alternative replies):
0=no chance of dozing
1=slight chance of dozing
2=moderate chance of dozing
3=high chance of dozing
Estimate of the probability of dozing o¡ (circle the right alternative):
How high is the probability that youwill doze o¡
10 s
Arousal
Obstruction of upper airways
Respiratory effort
Negative intrathoracic pressure
EEG
Apnoea, interruption of the flow of air
Respiratory motions of the chest continue
Abdominal respiratory motions continue
Decrease in oxygen saturation measured
by pulse oxymeter (SpO )2The situation No chance of dozing Slight Moderate High
Sittingandreading 0 1 2 3
WatchingTV 0 1 2 3
Sitting inactive in a public place (e.g. a theatre or ameeting) 0 1 2 3
As a passenger in a car for anhourwithout a break 0 1 2 3
Lyingdownto rest in the afternoonwhen circumstances permit 0 1 2 3
Sittingand talkincg to someone 0 1 2 3
Sittingquietly after a lunchwithout alcohol 0 1 2 3
In a car, while stopped for a fewminutes in tra⁄c 0 1 2 3
APPENDIX 3: EXAMPLESFROMSTUDIESONTHEPREVALENCEOFSLEEP
APNOEA
APPENDIX4:OBESITYGRADINGONTHEBASISOFBODYMASSINDEX(KG/M2)
APPENDIX5:CHECKLISTOFTHEGENERALPRACTITIONERWHENREFERRING
APATIENT TOASPECIALISTFORSLEEPEVALUATION
Study Country Testgroup Age (years) Criteria Prevalence (%)
(AHI)
Lavie (1983) Israel Men 421 410 0.9
Telakivi et al. (1987) Finland Men 41^50 420 1.4
Gislason et al. (1988) Sweden Men 30^69 45 1.4
Cirignotta et al. (1989) Italy Men 30^69 45 5.1
Stradlingand Crosby (1991) U.K. Men 35^65 45 4.6
Gleadhill (1991) Northern Ireland Men 40^64 410 + symptoms 0.8
Young et al. (1993) USA Men 30^60 45 + symptoms 4
Women 30^60 45 + symptoms 2
Bearparket al. (1995) Australia Men 40^65 410 10 %
Marin et al. (1997) Spain Men 418 410 2.2
Women 418 410 0.8 %
BMI Grade
o20 Underweight
20.0^24.9 Normal
25.0^29.9 Slightoverweight
30.0^34.9 Overweight
35.0^39.9 Obesity
440 Extreme obesity
1.Patient information
 weight, height,BMI, waist andneckcircumference
 occupation
 medication
 smoking
 use of alcohol
2. Symptoms (yes/no, duration)
 snoringeverynightornearlyeverynight
 apnoea episodes
 daytime fatigue
 accidents
 impairmentofthe ability towork
 Score on ESS410
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APPENDIX 6:WHENSHOULDOTHERSPECIALTIESBECONSULTED?
3.Concomitant illnesses
 asthma
 chronic obstructive pulmonarydisease
 hypertension
 arrhythmias
 coronaryheartdisease
 diabetes
 cerebral ischaemic attacks
 restless legs
 depression
4.Otolaryngological status (normal/narrow)
 nose
 soft palate, pharynx
 larynx
 occlusion
 size of tongue and jaw
X-ray and laboratoryresults
 Chest X-ray, sinus X-ray
 ECG
 Blood count,Fs-Cholesterol,Fs-Triglyceride,Fb-Glucose,S-TSH
 Flow volume spirometry, if expertevaluation is available
 Other results the referringdoctorconsiders important
 Cephalometric sleep apnoea X-ray
Dentist
abnormalocclusion andmandibular structure
evaluation and implementation of orthodontic treatment
evaluation andimplementationofmaxillofacial surgery (oral
andmaxillofacial surgery)
Pulmonary specialist
 exclusion/treatmentof asthma and COPD
exclusion/treatmentof other pulmonarydiseases
implementation of CPAP treatment (inmostunits)
ENTspecialist
 evaluation for pharyngeal surgery inpatientswithmild to
moderate sleep apnoea
 nasal congestion
 severenasalproblems during CPAP treatment
Paediatrician
exclusion/treatmentof other illnesses if necessary
Neurologist
 exclusion of neurological illnesses
 abnormalneurological status ¢ndings
 diagnosis of other sleep disorders
 evaluation of daytime alertness level
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APPENDIX 7: PARAMETERSUSEDINTHEMEASUREMENTOFLIMITEDAND
EXTENSIVESLEEPREGISTRATIONS INTHEDIAGNOSTICSOFSLEEPAPNOEA
 abnormal tiredness of a patient receiving CPAP treatment
 estimates of working ordriving ability
Psychiatrist
 exclusion/treatmentof psychiatric illnesses, particularly
depression
 problemswithtreatmentcompliance
Specialist inmedicine
 treatmentof problematic hypertension
 diagnosis and treatmentof cardiacdiseases
 treatmentof problematic endocrinological illnesses
 exclusion/treatmentof otherdiseases
Measuredparameters Limited sleep registration Extensive sleep registration
Respiratory air £ow + + (+) + + +
Intranasalpressure + + (+) + +
Respiratorymotion + + + + +
Oxygen saturation + + + + + +
Position + + + +
ECG + + + +
Pulse + + +
Limbmovement + + +
Snoring + + +
EEG  + + +
EMG  + + +
EOG  + + +
Usedmainly in research
CO2 of exhaled air  + +
Oesophagealpressure  + +
OesophagealpH  +
Additional EEG channels  +
EMGof intercostalmuscle  +
CO2 di¡using throughthe skin  +
Continuousmeasurement  + +
of bloodpressure
Other
 + +
+ + + = always included; + + (+) = often included; + + = possibly included; depending on the equipment; + = possibly
included; ^ = notusually included.
362 RESPIRATORYMEDICINEAPPENDIX 8:DEPRESSIONSCREEN (DEPS)
When depression is suspected, the DEPS patient questionnaire intended for use within primary health care may be a
useful tool. If the score in the test is499, the patient probably su¡ers from depression. (This informationmust not be
visible in the form given to the patient.)
Please answer the following questions by ticking the alternative that best describes your situation in the
lastmonth.
SLEEPAPNOEA 363APPENDIX 9: EXAMPLESOF TREATMENTPRINCIPLES FORSLEEPAPNOEAIN
PRIMARYHEALTHCARE
1. If the patient su¡ers from socially disturbing snoring but the ¢ndings of sleep registration are normal, support is
given by o¡ering guidance and, if necessary, by arranging further evaluations within primary health care on the
basis of the patient’s symptoms. Di¡erential diagnosis, e.g. for depression, should be considered if the patient
su¡ers from daytime fatigue.
2. A patientwho is not signi¢cantly overweight (BMIo30kg/m2), andwhose symptoms indicatemild sleep apnoea, is
onlyreferred to specialisedhealth care for an active treatmentevaluationwhennecessary.Guidance, treatment and
follow-upwithin primary health care.
3. An obese patient (BMI 430^35kg/m2) su¡ering from partial upper respiratory track obstruction or whose
symptoms indicate mild sleep apnoea is primarily given conservative treatment within primary health care. The
impact of weight loss is controlled by limited sleep registration. If weight loss does not promote the desired
results within a set time limit (e.g.1year), the patient is referred to specialised health care for an active treatment
evaluation.
4. A patient, who clearly su¡ers from position-related partial upper respiratory track obstruction or mild sleep
apnoea, can be treated by preventing him from sleeping supine.The e¡ect of the treatment should be controlled
by sleep registration. If position therapy does not yield the desired result, the patient is referred to specialised
health care for an active treatment evaluation.Weight loss as treatment should not be overlooked.
5. A patient su¡ering from moderate-to-severe sleep apnoea should be referred to specialised health care for an
active treatment evaluation regardless of his weight. According to the treatment and rehabilitation plan, cases of
mild and evenmoderate sleep apnoea can be treatedwithin primary health care in the future if agreed.
6. If thepatient’swork requires exceptional alertness (e.g. in tra⁄c) andhis score in the symptoms questionnaire (ESS,
Appendix 2) is11ormore, referring him to specialised health care for further evaluations should be considered.
7. Children with symptoms indicating sleep apnoea should always be referred to specialised health care for
examinations and an evaluation of the need for surgical treatment.
APPENDIX10: CONTRIBUTORYFACTORSOFLIFEMANAGEMENT, AND
PRINCIPLESOFWEIGHTLOSSANDWEIGHTCONTROL (BRIEF INSTRUCTIONS
ANDBASICTREATMENTINOBESITY)
During the pastmonth Never Sometimes Quite often Veryoften
Ihave su¡ered frominsomnia 0 1 2 3
Ihave beenmelancholy 0 1 2 3
Ihave feltthatdoinganythingrequires e¡ort 0 1 2 3
Ihave lacked energy 0 1 2 3
Ihave felt lonely 0 1 2 3
The future has seemedhopeless 0 1 2 3
Ihavenotenjoyed life 0 1 2 3
Ihave feltthat all joyhas disappeared frommylife 0 1 2 3
Ihave feltthat notevenmy family and friends canmakemehappy 0 1 2 3
Source: Salokangas et al. (1994).
Sector Centralpoints
Dietaryenergy  Themost importantthing is to reduce dietary fat.Withregard to health, it is recommended to
reduce the amountof animal (saturated) fats
364 RESPIRATORYMEDICINEAPPENDIX11: REALISTICTREATMENTCOSTSOFDIFFERENTSLEEPAPNOEA
TREATMENTS
 If the patientwishes to adopt a dietcontaininga restricted amountof energy (e.g. 5.0^7.5
MJ = 1200^1800 kcal/day), the diet shouldhave a varied content
 Unbalanced fashion diets are not recommended
 Reduction in alcohol consumption
Increased exercise  The importance of exercise is small in actualweight reduction, butgreat inweightcontrol
 Themain focus should be on increasingdailyphysical activity (functional exercise, everydayexercise)
 Moreover, the patient should be encouraged to exercise inhis free time
 The objective is anincrease of 4.2^8.4MJ (1000^2000 kcal) inweeklyenergyconsumption
Control of eating  Bettercontrol of eatingcan be reached byproviding instruction in eatinghabits and foodpurchases
 Themost important improvements: regularmeals, carefullyconsidered foodpurchases,
eliminating temptations to eat, concentrating inthemeal, and eatingmore slowly
Beliefs and attitudes
(cognitive issues)
 Focus on changing beliefs and impressions that are obstacles to changes
 Especiallydealingwithunrealistic expectations and feelings connected to‘‘succumbing
to the temptation’’andgivingup
 Diet and exercise diaries, incentives, methods of stress control andproblem solving,
and other supportivematerial can be used if necessary
A.Treatment ofa patient withmild sleep apnoea in health centres: the exemplary calculations have been provided by
a health centre located in theVarsinais^Suomi district in 2001
h
Doctor’s appointment inprimaryhealth-care 43
Basic laboratory tests a35
Individualweight loss and other guidance (public nurse) 30
Controlvisitto a health-care physician 43
Total 151
Furtherannual expenses
Visitto a health-care physician 43
Twovisits to a public nurse 61
Total 104
B. Exemplary calculation ofthe costs of CPAP treatment, which is implemented in specialised health care.
The prices used were valid in theVarsinais^Suomi district in 2001
Treatment initiation
Doctor’s appointment inprimaryhealth care (dg suspicion) 34
Visitto a specialistoutpatientdepartment 91
Consultation of another specialist (e.g.ENTspecialist) 86
Limited sleep registration 252
Doctor’s appointmentto learnthe results (outpatientdepartment) 49
Initiation of CPAP treatment + device 925
Follow-upvisit, patient + device (outpatientdepartment) 27
Total 1464
Furtherannual expenses
Patient + device once ayear (outpatientdepartment) 91
Masks, tubes and ¢lters/year 160
Total 251
C. Exemplary calculations: surgical treatment.The prices used were valid in theVarsinais^Suomi district in 2001
Doctor’s appointment inprimaryhealth care (dg suspicion) 34
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Limited sleep registration 252
LateralX-rayof the skull, and cephalometric analysis 52
Surgical intervention
GGA + hospital fees 1177
Check-upvisit 47
Check-up sleep registration 252
Total 1900
Other operations Total costs
Sagittal osteotomy/elongation ofthe lower jaw 1682
(+ orthodontics)
Maxillomandibular osteotomy 2943
(+orthodontics)
UPPP treatment 622
aThe laboratory tests of the examplewere: blood count,B-ESR,Fs-Cholesterol,Fs-HDLCholesterol,Fs-glucose,ECG,Urinalysis.
